These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

654 related items for PubMed ID: 19351838

  • 1. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.
    Wakimoto H, Kesari S, Farrell CJ, Curry WT, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, Jeyaretna DS, Debasitis J, Pruszak J, Martuza RL, Rabkin SD.
    Cancer Res; 2009 Apr 15; 69(8):3472-81. PubMed ID: 19351838
    [Abstract] [Full Text] [Related]

  • 2. Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.
    Sgubin D, Wakimoto H, Kanai R, Rabkin SD, Martuza RL.
    Stem Cells Transl Med; 2012 Apr 15; 1(4):322-32. PubMed ID: 23197811
    [Abstract] [Full Text] [Related]

  • 3. Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.
    Peters C, Paget M, Tshilenge KT, Saha D, Antoszczyk S, Baars A, Frost T, Martuza RL, Wakimoto H, Rabkin SD.
    J Virol; 2018 Aug 01; 92(15):. PubMed ID: 29793956
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.
    Jahan N, Lee JM, Shah K, Wakimoto H.
    Int J Cancer; 2017 Oct 15; 141(8):1671-1681. PubMed ID: 28567859
    [Abstract] [Full Text] [Related]

  • 5. Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.
    Esaki S, Nigim F, Moon E, Luk S, Kiyokawa J, Curry W, Cahill DP, Chi AS, Iafrate AJ, Martuza RL, Rabkin SD, Wakimoto H.
    Int J Cancer; 2017 Dec 01; 141(11):2348-2358. PubMed ID: 28801914
    [Abstract] [Full Text] [Related]

  • 6. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells.
    Kanai R, Wakimoto H, Martuza RL, Rabkin SD.
    Clin Cancer Res; 2011 Jun 01; 17(11):3686-96. PubMed ID: 21505062
    [Abstract] [Full Text] [Related]

  • 7. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
    Saha D, Wakimoto H, Peters CW, Antoszczyk SJ, Rabkin SD, Martuza RL.
    Clin Cancer Res; 2018 Jul 15; 24(14):3409-3422. PubMed ID: 29599413
    [Abstract] [Full Text] [Related]

  • 8. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.
    Duebgen M, Martinez-Quintanilla J, Tamura K, Hingtgen S, Redjal N, Wakimoto H, Shah K.
    J Natl Cancer Inst; 2014 Jun 15; 106(6):dju090. PubMed ID: 24838834
    [Abstract] [Full Text] [Related]

  • 9. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
    Cheema TA, Kanai R, Kim GW, Wakimoto H, Passer B, Rabkin SD, Martuza RL.
    Clin Cancer Res; 2011 Dec 01; 17(23):7383-93. PubMed ID: 21976549
    [Abstract] [Full Text] [Related]

  • 10. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J, Wakimoto H, Peters C, Martuza RL, Rabkin SD.
    J Natl Cancer Inst; 2017 Mar 01; 109(3):1-13. PubMed ID: 28376211
    [Abstract] [Full Text] [Related]

  • 11. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
    Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X, Bikfalvi A, Martuza RL, Kurtz A, Rabkin SD.
    Clin Cancer Res; 2006 Nov 15; 12(22):6791-9. PubMed ID: 17121900
    [Abstract] [Full Text] [Related]

  • 12. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.
    Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, Jeyaretna DS, Stemmer Rachamimov AO, Rabkin SD, Martuza RL.
    Neoplasia; 2013 Jun 15; 15(6):591-9. PubMed ID: 23730207
    [Abstract] [Full Text] [Related]

  • 13. Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.
    Uchida H, Marzulli M, Nakano K, Goins WF, Chan J, Hong CS, Mazzacurati L, Yoo JY, Haseley A, Nakashima H, Baek H, Kwon H, Kumagai I, Kuroki M, Kaur B, Chiocca EA, Grandi P, Cohen JB, Glorioso JC.
    Mol Ther; 2013 Mar 15; 21(3):561-9. PubMed ID: 23070115
    [Abstract] [Full Text] [Related]

  • 14. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
    Bommareddy PK, Wakimoto H, Martuza RL, Kaufman HL, Rabkin SD, Saha D.
    J Immunother Cancer; 2024 Apr 09; 12(4):. PubMed ID: 38599661
    [Abstract] [Full Text] [Related]

  • 15. Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells.
    Kardani K, Sanchez Gil J, Rabkin SD.
    Front Cell Infect Microbiol; 2023 Apr 09; 13():1206111. PubMed ID: 37325516
    [Abstract] [Full Text] [Related]

  • 16. Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses.
    Alayo QA, Ito H, Passaro C, Zdioruk M, Mahmoud AB, Grauwet K, Zhang X, Lawler SE, Reardon DA, Goins WF, Fernandez S, Chiocca EA, Nakashima H.
    Sci Rep; 2020 Mar 20; 10(1):5095. PubMed ID: 32198420
    [Abstract] [Full Text] [Related]

  • 17. Treatment of Human Glioblastoma with a Live Attenuated Zika Virus Vaccine Candidate.
    Chen Q, Wu J, Ye Q, Ma F, Zhu Q, Wu Y, Shan C, Xie X, Li D, Zhan X, Li C, Li XF, Qin X, Zhao T, Wu H, Shi PY, Man J, Qin CF.
    mBio; 2018 Sep 18; 9(5):. PubMed ID: 30228241
    [Abstract] [Full Text] [Related]

  • 18. An oncolytic HSV-1 vector induces a therapeutic adaptive immune response against glioblastoma.
    Reale A, Gatta A, Shaik AKB, Shallak M, Chiaravalli AM, Cerati M, Zaccaria M, La Rosa S, Calistri A, Accolla RS, Forlani G.
    J Transl Med; 2024 Sep 27; 22(1):862. PubMed ID: 39334370
    [Abstract] [Full Text] [Related]

  • 19. Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors.
    Tamura K, Wakimoto H, Agarwal AS, Rabkin SD, Bhere D, Martuza RL, Kuroda T, Kasmieh R, Shah K.
    Mol Ther; 2013 Jan 27; 21(1):68-77. PubMed ID: 22929661
    [Abstract] [Full Text] [Related]

  • 20. Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111.
    Friedman GK, Langford CP, Coleman JM, Cassady KA, Parker JN, Markert JM, Yancey Gillespie G.
    J Neurooncol; 2009 Nov 27; 95(2):199-209. PubMed ID: 19521665
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.